Synucleinopathies are a group of neurodegenerative disorders that include serious conditions such as Parkinson's disease and ...

An experimental RNA aptamer reduced toxic alpha-synuclein aggregates and improved disease-related features in preclinical ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a new screening technology, Aptamer-based T Lymphocyte ...

Small molecule inhibitors of proteins are invaluable tools in research and as starting points for drug development. However, their screening can be tedious, as most screening methods have to be ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...